Amorphous Solid Dispersion Formulation for FXIa Inhibitor Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of the FXIa inhibitor Compound (I) face challenges due to low aqueous solubility and stability issues, making oral administration difficult to achieve therapeutically effective blood levels.
Innovation Solution
Formulating Compound (I) as an amorphous solid dispersion in pharmaceutically relevant polymers like HPMCAS through spray drying, and solubilizing it in solutions with co-solvents and surfactants, ensuring stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If Compound (I) is formulated as a crystalline solid, then manufacturing is simpler, but aqueous solubility is low and bioavailability is poor
Solution Approach 1:
The patent changes the physical state parameter of Compound (I) from crystalline to amorphous form, which fundamentally alters its solubility characteristics. The amorphous form lacks the ordered crystal structure, enabling better interaction with aqueous solvents and significantly improving bioavailability while maintaining manufacturing feasibility through spray drying techniques
Solution Approach 2:
The patent creates a composite amorphous solid dispersion system combining Compound (I) with pharmaceutically acceptable carriers and polymers. This composite structure maintains the amorphous state of the drug while providing structural support and enhancing solubility, resolving the contradiction between manufacturing simplicity and aqueous solubility
2Quantity of substance
If Compound (I) is formulated as an amorphous solid dispersion, then aqueous solubility and bioavailability are enhanced, but physical and chemical stability deteriorates
Solution Approach 1:
The patent introduces pharmaceutically acceptable carriers and polymers as intermediary substances that mediate between the amorphous drug state and the environment. These carriers act as protective matrices that prevent crystallization and chemical degradation while maintaining the solubility benefits of the amorphous form, thus stabilizing the formulation
Solution Approach 2:
The patent modifies storage parameters by controlling temperature, humidity, and packaging conditions to preserve the amorphous state. By changing these environmental parameters, the formulation maintains both high solubility and stability over extended periods, resolving the stability-solubility contradiction
3Ease of operation
If Compound (I) is administered orally in conventional formulations, then administration is simple, but therapeutic plasma concentrations are not achieved
Solution Approach 1:
The patent changes the physical state of Compound (I) from crystalline to amorphous, which fundamentally improves its pharmacokinetic parameters. The amorphous form dissolves more rapidly and completely in gastrointestinal fluids, achieving therapeutic plasma concentrations through simple oral administration without requiring complex delivery systems
Solution Approach 2:
The patent develops a composite amorphous solid dispersion formulation that enhances the bioavailability of Compound (I). This composite structure facilitates better absorption across the intestinal membrane, achieving therapeutic plasma levels while maintaining the simplicity of oral administration
4Stability of the object's composition
If packaging controls such as desiccant and vapor barrier are used, then stability is improved, but device complexity and manufacturing cost increase
Solution Approach 1:
The patent develops a self-stabilizing amorphous solid dispersion formulation that inherently resists crystallization and degradation without requiring external packaging interventions. The formulation design itself provides the stability, eliminating the need for desiccants, vapor barriers, and complex packaging systems
Solution Approach 2:
The patent optimizes the formulation composition and storage parameters to achieve long-term stability under normal conditions. By changing the physical and chemical parameters of the formulation, it becomes stable enough to not require special packaging controls, reducing device complexity while maintaining stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous solid dispersion and solubilized formulations exhibit exceptional physical and chemical stability, maintaining therapeutic effectiveness with enhanced bioavailability and dissolution rates, reducing the need for packaging controls and achieving consistent drug levels in the bloodstream.
Implementation Method 1
Solid dispersion systems of amorphous drug have been investigated with the objective of inhibiting crystal growth and enhancing the dissolution of poorly water soluble drugs
Implementation Method 2
Compound (I) can be formulated as an amorphous solid dispersion in pharmaceutically relevant polymers such as hydroxypropyl methyl cellulose acetate succinate (HPMCAS) by spray drying
Data Source
AI summary
This invention relates to solid amorphous dispersions comprising Compound (I) having the formulaand one or more polymers or to solution formulations comprising Compound (I) and one or more co-solvents and surfactants. The formulations exhibit enhanced stability and bioavailability.